Bridgewater Chapter Upcoming Events Join PCCI

Member Profiles


Caroline Bell



Caroline Bell, PhD, is president and founder of PharmaFacts, an outgrowth of the expanded services of its parent company SSPCC, Inc. (Strategic Safety Pharmacology Consulting Consortium). She has been serving the Pharmaceutical Discovery and Development world since 2001. Although Safety Pharmacology remains an area of expertise, PharmaFacts services now include support on all aspects of the pharmaceutical industry and preclinical requirements (e.g. IND enabling studies and submission). With headquarters in the greater Philadelphia area, the company functions very much in a 21st century virtual mode, bringing together industry experts from all over the world, on an as needed basis, to partner with you in the facilitation and conduct of your entire Drug Discovery/Development Program.


Before founding SSPCC, Inc. in 2001, she was an Assistant Director of Safety Pharmacology at GlaxoSmithKline Pharmaceuticals where she:


Managed generation and interpretation of safety pharmacology data to support assessment of risk/safety profile of all development compounds for IND/NDA submissions, Held responsibilities for the oversight of preclinical safety assessment requirements on drug development teams Devised and directed introduction of new methods and technologies to ensure efficient, rapid, high quality core safety pharmacology screening, and Oversaw preclinical toxicological issues, regulatory reports, and executive management of operations and resources.


Dr. Bell held an academic position as Assistant Professor and Clinical Assistant Professor at New York Medical College conducting research on the regulation of blood pressure and renal function specializing in eicosanoids, the renin-angiotensin and kallikrein-kinin systems. She lectured on pharmacology to graduate and medical students and at affiliated hospitals.



Pharmafacts Services:


Late Stage Discovery - Screening and selection of potential drug candidates with associated efficacy and proof of concept across species in appropriate disease models as well as early formulation, stability and pharmacokinetic work.


Strategic IND-enabling GLP, GMP Programs - As a continuum to Discovery efforts, e.g.:

Toxicology Toxicokinetics Analytical / bioanalytical support Formulation and stability Core and supplemental safety pharmacology Data management Statistical assessment services


Investigative Programs - To address specific issues of each unique molecule

Pharmacokinetic / pharmacodynamic modeling, Design and investigation of optimal dosing regimens, dosing routes or absorption, Tier 2 preclinical studies paralleling phase I-IV Mechanism of drug action or toxicity.


Program Management

CROs - selection/quotes/oversight & monitoring Protocol design, data and report review Project facilitation QA Short term executive support


Regulatory Submissions

Electronic document management and eCTD filing Regulatory document compilation e.g. IND,CTA, NDA Strategic regulatory representation







Contact Info:

21 Pin Oaks Drive, Suite 101,

Phoenixville, PA 19460

Tel: (610) 933-9689

Fax: (610) 933-6312


Web: http:/


Good Company! Good Drink! Good Food! Good Program! Good Fun!


Site Navigation



Pharmaceutical Consulting Consortium International, Inc., or (610) 296-8086

Meetings Held at Embassy Suites - Valley Forge

888 Chesterbrook Blvd, Chesterbrook, Pennsylvania 19087

All content on this website is copyrighted and should not be reproduced without the consent of PCCI.

© Copyright 2016-2018



Tat Communication Inc